0001471242-14-000272.txt : 20140722 0001471242-14-000272.hdr.sgml : 20140722 20140722161848 ACCESSION NUMBER: 0001471242-14-000272 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20140721 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers FILED AS OF DATE: 20140722 DATE AS OF CHANGE: 20140722 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Oncologix Tech Inc. CENTRAL INDEX KEY: 0000799694 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] IRS NUMBER: 861006416 STATE OF INCORPORATION: NV FISCAL YEAR END: 0831 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-15482 FILM NUMBER: 14986790 BUSINESS ADDRESS: STREET 1: P.O. BOX 8832 CITY: KENTWOOD STATE: MI ZIP: 49518-8832 BUSINESS PHONE: 616-977-9933 MAIL ADDRESS: STREET 1: P.O. BOX 8832 CITY: KENTWOOD STATE: MI ZIP: 49518-8832 FORMER COMPANY: FORMER CONFORMED NAME: BESTNET COMMUNICATIONS CORP DATE OF NAME CHANGE: 20001219 FORMER COMPANY: FORMER CONFORMED NAME: WAVETECH INTERNATIONAL INC DATE OF NAME CHANGE: 19980225 FORMER COMPANY: FORMER CONFORMED NAME: WAVETECH INC DATE OF NAME CHANGE: 19920703 8-K 1 oclg8k07212014.htm OCLG8K07212014

U.S. SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C.20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): July 21, 2014

ONCOLOGIX TECH, INC.

(Name of Small Business Issuer as Specified in Its Charter)

	Nevada		0-15482		86-1006416
	(State or other jurisdiction of incorporation or organization)		(Commission File Number)		(I.R.S. Employer Identification No.)

1640 W. Pinhook Road, #200

Lafayette, LA 70508

(Address of principal executive offices)

(616) 977-9933

(Issuer’s telephone number)

Check the appropriate box below if the Form 8-K is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

p Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

pSoliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

p Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

p Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 5.02. Appointment of Certain Officers, Compensatory Arrangements of Certain Officers

On July 21, 2014, the Company appointed Mr. Harold Halman as Chief Operating Officer (COO) and President of its newly formed Subsidiary, American Medical Products and Technologies, Inc. In conjunction with this appointment, the Company and Mr. Halman entered into a three (3) year employment agreement which he will receive an annual base salary of $85,000, monthly allowances for health & dental insurance, automobile expenses, and bonus amounts paid quarterly based on his direct involvement of new revenue growth and earnings brought to the subsidiary.

Mr. Halman brings 20+ years of new business development, medical sales, marketing and operations experience to OCLG. Prior to joining the company, Harold was the Chief Executive Officer for Global Medical located in Phoenix, Arizona, a national provider for home medical equipment. Mr Halman has vast knowledge and industry experience in medical devices, home medical products and development of multi-tiered distribution strategies. Prior to Global Medical, Mr. Halman was CEO of his management consulting firm involved in M&A transactions, business turnarounds and business development projects.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

Dated: July 22, 2014
	ONCOLOGIX TECH, INC.

	By: /s/ Roy Wayne Erwin
	Roy Wayne Erwin, CEO and President

	By: /s/ Michael A. Kramarz
	Michael A. Kramarz, Chief Financial Officer